GSK

GSK plc demonstrates strong oncology pipeline momentum, highlighted by Mo-Rez's phase 1 success in platinum-resistant ovarian and endometrial cancers. Mo-Rez's impressive response rates support five global pivotal phase 3 trials planned for 2026, underscoring GSK's late-stage oncology expansion. GSK's ViiV Healthcare reports Cabenuva's superior viral suppression in HIV, and the company advances key acquisitions and registrational data in multiple myeloma and lung cancer.

GSK to cut up to 1,217 jobs in Belgium, L'Echo says

GSK PLC (LSE:GSK, NYSE:GSK) is expected to deliver a broadly in-line third quarter as weaker vaccine sales are offset by strength in HIV treatments and respiratory drug Nucala, according to RBC Capital Markets. The broker reiterated its Sector Perform rating and 1,975p price target ahead of GSK's results on 28 October, compared with a share price of 1,771p when the note was published.

Biotechnology stocks are showing signs of a renewed recovery, supported by a pickup in pharmaceutical mergers and acquisitions and investor interest in drug development pipelines. Key Takeaways: Big pharma acquisitions are hitting record highs to combat impending patent cliffs.

Investors need to pay close attention to GSK stock based on the movements in the options market lately.

SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with GSK.

For the first time, Viola Davis shares her experience with shingles Viola encourages adults 50 years and older to prioritize their health and have candid conversations about increased risks that come with aging The partnership is part of GSK's new national "Shingles, actually" disease education campaign PHILADELPHIA, Oct. 8, 2026 /PRNewswire/ -- GSK plc (LSE/NYSE: GSK) today announced a partnership with award-winning actress, producer and philanthropist Viola Davis to launch "Shingles, actually", a new educational campaign designed to spark conversations about the realities of aging, including the risk of shingles for adults 50 years and older. As part of the "Shingles, actually" campaign, Viola discusses her own experience with shingles for the first time, including its impact on her work and personal life, while encouraging the 50+ community to prioritize their health and start proactive conversations with their doctors.

GSK is accelerating its strategic transformation under new CEO Luke Miels, emphasizing M&A, pipeline expansion, and proactive HIV franchise management. At approximately 7x NTM EV/EBITDA, GSK offers an attractive risk/reward for investors willing to accept execution risk, meriting a Buy rating. The company is targeting over 20 Phase III starts in 2026, reinvesting GBP 1.9bn annual cost savings into R&D and M&A to offset the upcoming HIV patent cliff.

GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.

Investment bank Jefferies has kept its ‘buy' rating and 2,500p target on GSK PLC (LSE:GSK, NYSE:GSK), the FTSE 100 drugmaker, after a fireside chat with its chief scientific officer reinforced its view that B7H3 is one of GSK's most underappreciated opportunities. The target implies 35% upside from the prior close of 1,851p, while GSK had a market capitalisation of £74.9 billion.